Zevra Therapeutics Expands Executive Leadership Team
25 juin 2024 07h30 HE
|
Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
03 juin 2024 11h00 HE
|
Zevra Therapeutics
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on...
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
02 oct. 2023 07h30 HE
|
Zevra Therapeutics
Data generated to date indicate SDX is well-tolerated across all doses and both dosing regimens studied, laying the groundwork for future Phase 3 trial Topline data from completed trial expected in...
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
30 mars 2022 16h05 HE
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
21 mars 2022 07h30 HE
|
KemPharm
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep...
College of DuPage Student Awarded Honors Council of the Illinois Region Research Grant to Study Rare Sleep Disorder
16 juin 2020 10h05 HE
|
College of DuPage
Glen Ellyn, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- College of DuPage Psychology student Savannah Santos was recently awarded a $600 Margaret Messer Student Research Grant from the Honors Council of...